clinical trial · NCT07286006
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Immunovant Sciences GmbH·phase2·enrolling by invitation·n = 372
Graves' DiseaseIMVT-1402
brief summary
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
started
Jan 26, 2026
primary completion
Mar 1, 2030
completion
Mar 1, 2030
last updated
May 8, 2026
official title
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol